Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS) from its SEC filings: 2025 revenue $33.0 million (-35% vs the year before), net margin -1070%, free cash flow -$484.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $33.0 million |
| Revenue growth | -35% |
| Net income | -$353.0 million |
| Net margin | -1069.7% |
| Free cash flow | -$484.0 million |
| Diluted EPS | $-3.29 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +312% |
| Cash | $150.0 million |
| Long-term debt | $101.0 million |
| Share count, 1 year | +20% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.